Genes and pathology of non-small cell lung carcinoma.

While histopathology has traditionally been the cornerstone of treatment decisions in the management of lung cancer patients, the complexity and heterogeneity of histological classification has had a limited impact in the routine practice of oncology. This has changed dramatically in the last few years, owing to discoveries of genomic aberrations and results of clinical trials of novel and targeted therapies. These discoveries have resulted in a new way of classifying non-small cell lung cancer (NSCLC), based on the occurrence of putative or proven driver and targetable genomic changes. The rapidity by which the landscape of mutation and genomic changes is being identified also has led to a new paradigm and approaches to pathological diagnosis of NSCLC. In this context, international consortia have proposed new classifications of lung adenocarcinoma and guidelines for molecular testing in lung cancer and have provided concrete recommendations on new ways to practice lung cancer pathology.

[1]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[3]  M. Jin,et al.  Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues , 2013, PloS one.

[4]  A. Nicholson,et al.  Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[5]  T. Kohno,et al.  ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases , 2013, The American journal of surgical pathology.

[6]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Niruthika Sritharan,et al.  Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.

[8]  L. Chirieac,et al.  Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Y. Totoki,et al.  Mouse Model for ROS1-Rearranged Lung Cancer , 2013, PloS one.

[10]  Pora Kim,et al.  A High-Dimensional, Deep-Sequencing Study of Lung Adenocarcinoma in Female Never-Smokers , 2013, PloS one.

[11]  F. Hirsch,et al.  A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[13]  Tatsuo Ito,et al.  Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions , 2012, Clinical Cancer Research.

[14]  Herbert Waldmann,et al.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.

[15]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[16]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[17]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[18]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[19]  E. Shaw,et al.  Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Cappuzzo,et al.  Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[21]  P. Jänne,et al.  Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[22]  Iver Petersen,et al.  Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study , 2012, Modern Pathology.

[23]  D. Nonaka.  A Study of &Dgr;Np63 Expression in Lung Non-Small Cell Carcinomas , 2012, The American journal of surgical pathology.

[24]  T. Schmid,et al.  Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. , 2012, American journal of clinical pathology.

[25]  T. Gu,et al.  Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.

[26]  R. T. Bronson,et al.  The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. , 2012, Cancer research.

[27]  I. Petersen,et al.  FGFR1 expression and gene copy numbers in human lung cancer , 2012, Virchows Archiv.

[28]  Michael Thomas,et al.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Giuseppe Pelosi,et al.  p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma , 2012, Modern Pathology.

[31]  K. Kerr.  Personalized medicine for lung cancer: new challenges for pathology , 2012, Histopathology.

[32]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[33]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[34]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[35]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[36]  Michael A. Davies,et al.  Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[37]  Å. Helland,et al.  Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  M. Ladanyi,et al.  Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.

[39]  A. Iafrate,et al.  Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers , 2011, PloS one.

[40]  David Haussler,et al.  Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma , 2011, Proceedings of the National Academy of Sciences.

[41]  S. Dacic,et al.  Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. , 2011, American journal of clinical pathology.

[42]  G. Jayson,et al.  A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  C. Sima,et al.  Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens , 2011, Modern Pathology.

[44]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[45]  P. Hou,et al.  Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC) , 2011, BMC Cancer.

[46]  Hyojin Kim,et al.  Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[47]  Ping Yang,et al.  Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[49]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  Nathanael S Gray,et al.  Discovery of selective irreversible inhibitors for EGFR-T790M. , 2011, Bioorganic & medicinal chemistry letters.

[51]  G. Scagliotti,et al.  Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[53]  B. Job,et al.  Genomic Aberrations in Lung Adenocarcinoma in Never Smokers , 2010, PloS one.

[54]  Samuel Leung,et al.  Optimal Immunohistochemical Markers For Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor Samples , 2010, The American journal of surgical pathology.

[55]  J. Wesche,et al.  Roles of Fibroblast Growth Factor Receptors in Carcinogenesis , 2010, Molecular Cancer Research.

[56]  David P. Davis,et al.  Diverse somatic mutation patterns and pathway alterations in human cancers. , 2010, Nature.

[57]  T. Nishimura,et al.  Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  Jih-Hsiang Lee,et al.  Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors , 2010, Proceedings of the National Academy of Sciences.

[59]  U. Motosugi,et al.  Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings , 2010, Japanese Journal of Radiology.

[60]  M. Antoine,et al.  Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. , 2010, Lung cancer.

[61]  K. Kerr,et al.  Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[62]  E. Brambilla,et al.  SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas , 2010, PloS one.

[63]  Wim Timens,et al.  Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. , 2009, Lung cancer.

[64]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[65]  S. Ou,et al.  Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[66]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[68]  A. Sandler,et al.  Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[69]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[70]  Ho Yun Lee,et al.  Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. , 2009, Lung cancer.

[71]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[72]  A. Borczuk,et al.  Invasive Size is an Independent Predictor of Survival in Pulmonary Adenocarcinoma , 2009, The American journal of surgical pathology.

[73]  M. Ittmann,et al.  Paths of FGFR-driven tumorigenesis , 2009, Cell cycle.

[74]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[75]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[76]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[77]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[78]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[79]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[80]  H. Sugimura,et al.  PIK3CA mutation and amplification in human lung cancer , 2007, Pathology international.

[81]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[82]  A. Iafrate,et al.  Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. , 2007, The Journal of molecular diagnostics : JMD.

[83]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[84]  Heather N Watson,et al.  Histologic features are important prognostic indicators in early stages lung adenocarcinomas , 2007, Modern Pathology.

[85]  W. Pao,et al.  Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[86]  H. Sasaki,et al.  PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.

[87]  S. Lam,et al.  High resolution analysis of non‐small cell lung cancer cell lines by whole genome tiling path array CGH , 2006, International journal of cancer.

[88]  C. MacAulay,et al.  Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression , 2005, Oncogene.

[89]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[90]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[91]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[92]  F. Kabbinavar,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Keara M. Lane,et al.  Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) , 2003, Genes, chromosomes & cancer.

[94]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[95]  N. Goldstein,et al.  Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. , 2001, American journal of clinical pathology.

[96]  A. Nicholson,et al.  Reproducibility of the WHO/IASLC grading system for pre‐invasive squamous lesions of the bronchus: a study of inter‐observer and intra‐observer variation , 2001, Histopathology.

[97]  S. Hirohashi,et al.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995, Cancer.

[98]  Christopher R. Cabanski,et al.  Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. , 2013, Archives of pathology & laboratory medicine.

[99]  W. Lam,et al.  Applications of array-CGH for lung cancer. , 2013, Methods in molecular biology.

[100]  Comparative Genomic Hybridization: Implications of the , 2013 .

[101]  Paul D. Smith,et al.  Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer , 2012 .

[102]  S. Kobayashi,et al.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.

[103]  I. Petersen,et al.  EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC , 2010, Virchows Archiv.

[104]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[105]  D. Garfield,et al.  Bronchioloalveolar carcinoma: the case for two diseases. , 2008, Clinical lung cancer.

[106]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[107]  O. Auerbach,et al.  APPLICATION OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUNG CARCINOMA TO BIOPSY MATERIAL. , 1965, The Annals of thoracic surgery.